Liquid biopsy

What it is

Liquid biopsy is a test, usually from blood, that looks for tumour material outside the tumour itself, and it can help guide cancer care without a surgical tissue sample in some situations. The most important practical fact is that liquid biopsy is not a complete replacement for standard tissue biopsy in many patients, especially when a new cancer diagnosis still needs confirmation under the microscope.

Instead of removing a piece of the tumour, liquid biopsy analyzes cancer-related material shed into body fluids. Blood is the most common sample, but urine, cerebrospinal fluid, pleural fluid, and other fluids may sometimes be used. Depending on the assay, the test may look for circulating tumour DNA (ctDNA), circulating tumour cells (CTCs), RNA, exosomes, proteins, or methylation patterns.

In cancer care, liquid biopsy is mainly used for 3 broad purposes:

Use	What it may help with	Important caveat
Molecular profiling	Finding targetable mutations such as resistance or driver alterations	A negative result does not rule out a mutation
Monitoring	Tracking response, minimal residual disease, or relapse risk	Clinical usefulness varies by cancer type and assay
Early detection / screening	Looking for cancer signals before symptoms	Still evolving and not established for routine use in most people

For patients in India, the appeal is clear: a blood-based test may be easier to repeat than an invasive biopsy, especially when the tumour is hard to reach or the patient is unwell. But availability, cost, lab quality, and how the result will change treatment are all important before ordering it.

How it works

Tumours can release cells and fragments of genetic material into the bloodstream and other body fluids. Liquid biopsy technologies try to capture and analyze these signals.

Common analytes include:

1. ctDNA: small fragments of tumour-derived DNA in blood. These can show mutations, copy-number changes, or methylation patterns.
2. CTCs: intact cancer cells circulating in blood. These are less common than ctDNA and can be technically harder to detect.
3. Exosomes and other extracellular vesicles: tiny particles released by cells that may carry RNA, DNA, and proteins.
4. Cell-free RNA or protein markers: used in some research and commercial platforms.

The main challenge is signal strength. Some cancers shed a lot of material into blood, while others shed very little. Early-stage tumours often release less ctDNA than advanced cancers, which is one reason early detection remains difficult. Results can also be affected by non-cancer DNA changes from normal aging blood cells, called clonal haematopoiesis, which may create false-positive findings if not handled carefully.

Evidence and uses

Liquid biopsy already has real clinical uses, but its value depends on the exact cancer, the exact test, and the clinical question.

Where it is most established

In advanced cancers, especially some lung cancers, liquid biopsy can help identify actionable mutations when tissue is limited, unsafe to obtain, or insufficient for full molecular testing. It can also detect resistance mutations that appear after treatment. In this setting, many oncology teams use plasma-based genomic testing as a complement to tissue testing.

Monitoring disease over time

Because blood can be sampled repeatedly, liquid biopsy is attractive for tracking tumour burden, treatment response, and relapse risk. ctDNA may fall when treatment is working and rise before scans show progression. Minimal residual disease testing after surgery or chemotherapy is an active area of research and early clinical use in selected cancers, but standards are still developing.

Early detection and screening

This is one of the most discussed uses, but also one of the least settled. Multi-cancer early detection tests and organ-specific assays are being studied, yet performance can vary by cancer stage and tumour type. A positive screening-style liquid biopsy usually needs follow-up imaging and often a tissue diagnosis. Evidence in humans is promising but still limited for routine population-wide screening.

Examples of current and emerging applications

Clinical situation	Potential role of liquid biopsy	Current status
Advanced non-small cell lung cancer	Detect targetable mutations or resistance mutations	Established adjunct in many settings
Tumour hard to biopsy	Provide molecular information from blood	Useful, but negative tests may need tissue follow-up
After curative-intent treatment	Detect minimal residual disease	Emerging; not uniform across cancers
Cancer screening in healthy people	Detect cancer signals early	Investigational or limited use

Health-system reviews note that implementation also depends on cost-effectiveness, laboratory standards, turnaround time, and equitable access. That matters in India, where advanced molecular testing may be concentrated in larger urban centres and private hospitals.

Diagnosis / how it's measured

A liquid biopsy is not one single test. The report depends on the platform used.

Typical steps include:

1. Blood or other fluid collection.
2. Separation of plasma or target cells.
3. Molecular analysis using methods such as PCR or next-generation sequencing.
4. Interpretation in the context of the patient's cancer type, stage, treatment history, and imaging.

Key points when reading a result:

• Positive finding: may identify a mutation, methylation signal, or other cancer-associated marker that can help guide next steps.
• Negative finding: does not always mean there is no cancer or no mutation. The tumour may not be shedding enough material.
• Concordance with tissue: sometimes high, but not perfect. Tissue and liquid biopsy can give complementary information.
• Need for confirmation: for a new diagnosis, pathology from tissue is still often required.

A good report should state the specimen type, genes or markers tested, assay limits, and whether the result is intended for diagnosis, treatment selection, or monitoring.

When to see a clinician

Ask an oncologist about liquid biopsy if a tumour biopsy is risky, difficult, or has not provided enough tissue for molecular testing. It may also be worth discussing if your doctor wants to look for a targetable mutation, check for resistance after treatment stops working, or monitor for recurrence in a setting where ctDNA testing is being used.

Before doing the test, ask 3 practical questions:

1. What decision will this result change?
2. If the test is negative, will I still need a tissue biopsy?
3. Is the laboratory validated for this specific cancer and purpose?

Patients should also ask about cost, turnaround time, and whether the result is accepted by the treating hospital or tumour board. In India, these issues can vary widely between centres.

Limitations and open questions

Liquid biopsy is promising, but it has clear limits. Sensitivity can be low in early-stage disease, low-volume disease, or tumours that do not shed much DNA into blood. False negatives are a major reason it cannot yet replace tissue biopsy in many situations.

False positives and over-interpretation are also concerns. Some detected DNA changes may come from clonal haematopoiesis rather than the tumour. Screening-style tests can find a cancer signal without clearly identifying where the cancer is, which can lead to extra scans and procedures.

Other open questions include which patients benefit most, how often testing should be repeated, how to standardise minimal residual disease assays, and whether broad use improves survival enough to justify cost. Evidence is strongest for selected advanced cancers and weaker for routine screening and some monitoring uses.

The safest approach is to treat liquid biopsy as one tool within cancer care, not a stand-alone answer. Results should be interpreted by an oncologist or molecular tumour board alongside symptoms, scans, pathology, and standard lab tests.